Authors
Latest:
Dr. De Censi on the Hope for Biosimilars in the United StatesAndrea De Censi, MD, director of the medical oncology unit at the National Hospital E.O. Ospedali Galliera–SC Oncologia Medica in Genoa, Italy, discusses the hope for biosimilars in the United States.
Latest:
Dr Necchi on Responses With TAR-200 According to PD-L1 Status in NMIBCAndrea Necchi, MD, discusses treatment with TAR-200 by PD-L1 expression in BCG-unresponsive, high-risk non–muscle-invasive bladder cancer with CIS.
Latest:
Adding CAR T-Cell Therapy to the Electronic Medical RecordAndrea Price, APN, discusses adding CAR T-cell therapy to the electronic medical record.
Latest:
The Applications of a Mixed Reality LaboratoryAndrea Sboner, MS, PhD, assistant professor of computational genomics in computational biomedicine and of pathology and laboratory medicine, Weill Cornell Medicine, discusses the applications of a mixed reality laboratory.
Latest:
Dr. Barrio on Neoadjuvant Chemo to De-Escalate Axillary Node Dissection in Breast CancerAndrea V. Barrio, MD, FACS, discusses how the use of neoadjuvant chemotherapy can help de-escalate axillary node dissection in select patients with breast cancer. Dissection can be a morbid procedure with longterm risks of lymphoma, impacting the quality of life for many patients.
Latest:
Dr. Wang-Gillam on Next Steps With Defactinib Combo in Pancreatic Ductal AdenocarcinomaAndrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.
Latest:
Dr. du Bois on Pazopanib in Advanced Ovarian CancerAndreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Latest:
Dr. du Bois on the Potential Impact of Cytoreductive Surgery in Ovarian CancerAndreas du Bois, MD, PhD, a professor of gynecologic oncology at Kliniken Essen Mitte, discusses the potential impact of cytoreductive surgery in ovarian cancer.
Latest:
Dr. Hochhaus on TFS With Nilotinib in Patients With CMLAndreas Hochhaus, MD, professor of Internal Medicine, Hematology and Oncology, interim head of the Department of Hematology and Medical Oncology, University Medical Center Jena in Germany, discusses results of the phase II ENESTFreedom study, which examined treatment-free survival (TFS) in patients with chronic myeloid leukemia (CML) who received frontline nilotinib (Tasigna).
Latest:
Dr. Kaubisch on the REACH Trials in HCCAndreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.
Latest:
Dr. Poveda on the Results of the SOLO2 Trial in Ovarian CancerAndres Poveda, MD, discusses the results of the phase 3 SOLO2 trial in advanced ovarian cancer.
Latest:
Emerging CD123-Targeted Therapies for BPDCN: Pivotal Trial Insights and Future PotentialDr. Andrew Lane discusses CD123-targeted therapies, particularly the antibody-drug conjugate pivekimab sunirine (PVEK), for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). He notes PVEK's promising response rates and safety profile from early trial data, including lower risk of concerning side effects like capillary leak syndrome that can occur with the currently approved CD123-targeting agent tagraxofusp. In closing, he emphasizes accurately diagnosing BPDCN via expert hematopathology review and referral to specialized centers taking a cross-disciplinary approach, as combining emerging CD123-directed therapies with stem cell transplant as appropriate gives the best chance for optimal BPDCN management.
Latest:
Dr. Branagan on Novel Induction Therapies With Transplant in MyelomaAndrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.
Latest:
Liposomal Encapsulation of Radiotherapeutics Holds Promise in Treating GlioblastomaAndrew Brenner, MD, PhD, discusses how liposomal encapsulation of radiotherapeutics holds significant promise as a treatment of glioblastoma.
Latest:
Future Directions in Care for HER2+ Breast CancerBefore closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.
Latest:
Future Directions for the Management of HR+ Breast CancerAndrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
Latest:
Melanoma Expert Focuses on Finding the Next Best TherapyClinical trials demand extreme rigor. A mistake in trial design, like a bookkeeping error, can lead regulators to reject a potentially valuable drug. Many researchers dislike this intense focus on dotting i’s and crossing t’s. Omid Hamid, MD, enjoys the challenge.
Latest:
Dr. Zelenetz on Progress Made in MCL TreatmentAndrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.
Latest:
Dr. Dannenberg on Inflammation and Increased Breast Cancer RiskAndrew Dannenberg, MD, professor of Medicine, Weill Cornell Medical College, discusses the association between breast inflammation and breast cancer risk.
Latest:
Dr. Hendifar Discusses the Future Treatment of NETsAndrew E. Hendifar, MD, medical oncology lead for the Gastrointestinal Disease Research Group, Cedars-Sinai Medical Center, discusses the future treatment landscape for patients with neuroendocrine tumors (NETs).
Latest:
Personalizing Treatment for HPV-Related Head and Neck CancerOver the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.
Latest:
Dr. Hendifar on PEGPH20 Survival Impact in High Hyaluronan Pancreatic CancerAndrew Hendifar, MD, MPH, Assistant Professor of Medicine at Cedars Sinai Medical Center and the David Geffen School of Medicine, discusses the use of a PEGylated form of rHuPH20 (PEGPH20) added to nab-paclitaxel/gemcitabine for pancreatic cancer patients with high levels of hyaluronan (HA).
Latest:
Dr Armstrong on the FDA Approval of Abiraterone/Olaparib Combination in BRCA-mutated mCRPCAndrew J. Armstrong, MD, MSc, discusses the significance of the FDA approval of olaparib plus abiraterone acetate and prednisone or prednisolone in patients with BRCA-mutated metastatic castration-resistant prostate cancer.
Latest:
Dr. Brenner on the Link Between Breast Cancer and ObesityAndrew J. Brenner, MD, PhD, from the Cancer Therapy Research Center, discusses the link between obesity and breast cancer outcomes.
